Roche's Ocrevus is one of the best MS launches ever, but Tecentriq in I-O? Not so much
admin 26th April 2018 Uncategorised 0Roche expects biosimilars to siphon sales from several top meds, and in Europe, they’re already taking their toll. Its hotly anticipated I-O drug Tecentriq has lost sales momentum, at least for now. The good news? Roche says it’s shepherding one of the
read more